Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V (NCT05268289)
An Adaptive, Randomized, Double-blind, Dose Exploration, Parallel Group, Placebo Controlled, Multicenter Phase 2 Trial to Evaluate the Efficacy, Safety and Tolerability of LNP023 in Combination With Standard-of-care With and Without Oral Corticosteroids in Patients With Active Lupus Nephritis Class III-IV, +/- V
🩺 Plain-English Summary (8th-Grade Level)
The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.
Who can join: Review the eligibility criteria below.
Location: AKDHC Medical Research ServicesLLC — Phoenix, Arizona
Age range: 18 Years to 100 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (103 Sites)
Showing the first 25 of 103 sites.
- AKDHC Medical Research ServicesLLC — Phoenix, Arizona
- Kaiser Permanente Fontana — Fontana, California
- Univ Calif Irvine — Irvine, California
- Ronald Reagan UCLA Medical Center — Los Angeles, California
- Loma Linda University — San Bernardino, California
- Olive View UCLA Medical Center — Sylmar, California
- University of Colorado Denver — Aurora, Colorado
- Royal Research Corp — Hollywood, Florida
- Mayo Clinic Jacksonville — Jacksonville, Florida
- Nephrology Associates Of Central FL — Orlando, Florida
- Florida Kidney Physicians — Riverview, Florida
- Florida Kidney Physicians — Riverview, Florida
- Nep Assoc of Northern Illinois — Hinsdale, Illinois
- Wichita Community Clcl Onco Program — Wichita, Kansas
- Ochsner Health System — New Orleans, Louisiana
- Johns Hopkins Hospital — Baltimore, Maryland
- Brigham and Womens Hosp Harvard Med School — Boston, Massachusetts
- Mayo Clinic Rochester — Rochester, Minnesota
- University of Nebraska Medical Center — Omaha, Nebraska
- Stony Brook Internists PC — East Setauket, New York
- Cleveland Clinic Foundation — Cleveland, Ohio
- Temple University — Philadelphia, Pennsylvania
- Allegheny Health Network — Pittsburgh, Pennsylvania
- Dallas Nephrology Associates — Dallas, Texas
- Prolato Clinical Research Center — Houston, Texas
📞 Contact the Study Coordinator
Phone: (888) 669-6682
Email: novartis.email@novartis.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lupus Nephritis
- KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis — Palo Alto, California
- Daratumumab to Treat Active Lupus Nephritis — Rochester, Minnesota
- A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis — Birmingham, Alabama
- Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis — Glendale, Arizona
- An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases — Phoenix, Arizona
- Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis — Birmingham, Alabama
Explore by condition: All Lupus Nephritis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.